Press Release – COVID-19 Vaccine Corporation New Zealand most experienced vaccine researcher COVID-19 Vaccine Corporation (CVC) has signed a collaboration agreement with not-for-profit Vaccine Formulation Institute (VFI) in Switzerland. CVC began its vaccine production efforts in 2020 and is continuing …
New Zealand most experienced vaccine researcher COVID-19 Vaccine Corporation (CVC) has signed a collaboration agreement with not-for-profit Vaccine Formulation Institute (VFI) in Switzerland.
CVC began its vaccine production efforts in 2020 and is continuing to make progress with its T cell COVID-19 vaccine. CVC’s vaccine is designed to induce immunity to both current and yet unknown variants of the SARS-CoV-2 virus, and will act as an enhancer to existing vaccines currently available on the market.
Press Release – COVID-19 Vaccine Corporation
New Zealand most experienced vaccine researcher COVID-19 Vaccine Corporation (CVC) has signed a collaboration agreement with not-for-profit Vaccine Formulation Institute (VFI) in Switzerland.
CVC began its vaccine production efforts in 2020 and is continuing to make progress with its T cell COVID-19 vaccine. CVC’s vaccine is designed to induce immunity to both current and yet unknown variants of the SARS-CoV-2 virus, and will act as an enhancer to existing vaccines currently available on the market.
“It is particularly exciting to work with VFI. We are now working with individuals that are global experts in the use, application and formulation of vaccine adjuvants. We have been talking to them for quite a while now, and with the good progress we are making in the lab we are optimistic about the future,” says CVC Chief Executive Dr Robert Feldman.
Saturday, 10 July 2021, 12:51 pm
New Zealand most experienced vaccine researcher COVID-19
Vaccine Corporation (CVC) has signed a collaboration
agreement with not-for-profit Vaccine Formulation Institute
(VFI) in Switzerland.
CVC began its vaccine production
efforts in 2020 and is continuing to make progress with its
T cell COVID-19 vaccine. CVC’s vaccine is designed to
induce immunity to both current and yet unknown variants of
the SARS-CoV-2 virus, and will act as an enhancer to
existing vaccines currently available on the
market.
“It is particularly exciting to work with
VFI. We are now working with individuals that are global
experts in the use, application and formulation of vaccine